🔗 Share this article

While the US proceeds with historic changes to its vaccine recommendations, one figure has surfaced unexpectedly: Dr. Tracy Beth Høeg, a US-based sports physician and epidemiologist who rose to prominence by casting doubt on COVID-19 vaccines throughout the pandemic and has zeroed in on possible deaths after COVID-19 vaccination in her short tenure at the Food and Drug Administration.

Planned Shifts to Pediatric Immunization Schedule

Agency leaders were set to unveil major revisions to the pediatric immunization program in December, aligning the US with the Danish national calendar, sources say – a significant shift that would put the US at odds with many the global community with no evidence for benefit. The announcement has been delayed until the new year.

Instead of Vinay Prasad, Dr. Høeg is set to speak at the meeting. She was recently named acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to run the office this calendar year.

A New Direction at the Regulatory Body

The acting appointment could signify a closer partnership between the drug and biologics centers as Høeg and Prasad consolidate power at the regulatory agency – and it signals a greater focus upon reevaluating previously authorized vaccines at the FDA.

Høeg has repeatedly called for halting specific pediatric immunization guidelines in the US to become more in line with Denmark's approach, a country with nationalized medicine and a population about the size of the state of Wisconsin.

To date comments, she has continued to focus on vaccination policy – traditionally the responsibility of Prasad, chief of the FDA’s vaccine center – rather than medication approval.

Doubts Over Expertise

Høeg has no obvious background in drug development, approval processes or leadership, which has been standard for previous directors of the CBER. She has served at the FDA as a key advisor to the commissioner and CBER since spring.

“She appears not to have any of the qualifications” for leading the drug-regulation department, said Jonathan Howard. “She’s never run a randomized controlled trial. She is not versed in running a large organization. She lacks background in industry regulation.”

Former directors of the center would “be deeply familiar with regulatory frameworks and the underlying principles of medication creation”, noted a former acting FDA commissioner. “Frankly, she doesn’t have the type of experience that prior appointees who headed the center have had.”

This division has an immense workload at the FDA, the former commissioner pointed out.

“The public just pays attention on the innovative therapies, but the generic program clears a multitude of generic drugs. There’s a biosimilars division, OTC medication office and more, and each of these have to be supervised,” she noted. “The thing you overlook, that’s the thing that I always told people is going to bite you.”

Furthermore, a significant administrative component to the job, which manages over 5,000 staff members. “It is a huge management job, if you do it right,” the former official concluded.

Official Statement and Controversial Programs

When asked about inquiries about Høeg’s fitness for the role and whether this assignment represents greater collaboration among agency officials on immunizations, a press secretary responded that the “inquiries stem from inaccurate presumptions”.

“This background is consistent with the functions of her position,” the spokesperson stated, citing the period Høeg spent guiding the FDA commissioner on “medication safety and oversight research, including computational safety modeling and immunization monitoring”.

In her interim role, Dr. Høeg assumes responsibility for the commissioner’s recently launched fast-track approval initiative, a controversial one-day medication authorization process that allegedly worried her predecessors. “By what process are these medications being chosen for this expedited pathway? Who makes the decisions?” Dr. Howard asked. “There is a lot of confidentiality going on at the FDA right now.”

In general, he stated, “the FDA appears to be shifting towards laxer oversight of all drugs, except for vaccines.”

Documented Past Work on Vaccines

Concerning vaccines, Høeg has a more established, if concerning, history, some experts have noted. She released a research paper using unverified volunteer-provided data to determine the incidence of heart inflammation following COVID-19 immunization. She counseled the state of Florida surgeon general Joseph Ladapo, who reportedly have changed statistics to imply COVID-19 vaccines are pose a greater threat than they are.

Part of her “policy goals” for the current government encompassed changing regulations for recently developed shots and halting “optional” vaccines, she remarked following the vote on a online show. At the agency, Høeg has reportedly proposed barring young men from obtaining Covid vaccinations.

“She’s an all-around true believer who begins with her preconceived notions and works backwards to retrofit the evidence in a very deceptive, dishonest way,” Dr. Howard stated.

Taking Control and a “Push for Payback”

Dr. Høeg aligned with fellow dissenters, {like|